Skip to main content
Ovoca Bio Plc logo

Ovoca Bio Plc — Investor Relations & Filings

Ticker · OVXA ISIN · IE00B4XVDC01 LEI · 213800ST2AK5XQ1O5207 IR Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2019-07-25 Regulatory Filings
Country IE Ireland
Listing IR OVXA

About Ovoca Bio Plc

https://ovocabio.com/

Ovoca Bio is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. Its lead product candidate is Orenetide, a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack of sexual desire and representing a significant area of high unmet medical need. The company is advancing Orenetide through clinical development for major global markets and has filed for marketing approval in the US and Europe. Ovoca Bio's strategy includes leveraging its patent portfolio and considering licensing or collaboration opportunities to accelerate the availability of its product candidates to patients.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1477 characters) and contains the header 'RNS Number : 7750G', indicating it is a regulatory news service announcement from the London Stock Exchange. The content describes a 'Price Monitoring Extension' for an auction call period, which is a specific operational notice related to trading mechanics, not a core financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit into the more specific categories (like DIRS, DIV, or CAP), the most appropriate classification is the general regulatory filing fallback category.
2019-07-25 English
Annual Report and Notice of AGM
Report Publication Announcement Classification · 100% confidence The document is an RNS announcement dated June 28, 2019, titled "Publication of 2018 Annual Report and Notice of AGM". It explicitly states that the 2018 Annual Report and Financial Statements have been published and provides a link to view them. It also announces the Notice of AGM. Because the document's primary function is to announce the publication of the Annual Report and the AGM Notice, and it is short (under 5,000 characters) and directs the reader to external links for the full documents, it fits the definition of a Report Publication Announcement (RPA) rather than the full 10-K or AGM-R document itself. The presence of the RNS number confirms it is a regulatory announcement.
2019-06-28 English
US and EU Clinical Development Plans
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated April 23, 2019. It announces that Ovoca Bio plc is commencing the preparation of a Clinical Development Plan (CDP) for its drug candidate, Libicore, for US and EU regions, involving regulatory bodies like BfArM and the US FDA. This is a specific operational update concerning clinical strategy and regulatory interaction. Since it is a formal announcement released via RNS (Regulatory News Service) and details a specific corporate action/update that doesn't fit the more specific categories like ER, 10-K, or DIV, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially LTR if it were about legal proceedings, but here it is about development plans. Given the context of an RNS release detailing a business/development update, RNS is the most appropriate general classification if a more specific one like 'LTR' (Legal Proceedings) or 'CAP' (Financing) does not apply. It is not a full report, so RPA is less likely than RNS for this type of content.
2019-04-23 English
Operational Update & Additional Investment in IVIX
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated March 27, 2019. It provides an 'Operational Update' regarding a subsidiary (IVIX) and announces the 'Acquisition of Additional Interest in IVIX'. It details clinical trial progress, management changes (resignation and assumption of duties), and a strategic business update, concluding with standard RNS disclaimers. This format—a brief, timely announcement of material operational and corporate events, disseminated via the RNS system—is characteristic of a general regulatory announcement that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (4792 chars) is not extremely short, but the content is clearly an announcement rather than the full report itself.
2019-03-27 English
Primary Endpoints Met in Libicore Phase III Study
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory news service announcement. The content details positive top-line results from a Phase 3 clinical trial for a drug candidate (Libicore/BP-101) and announces the intention to file for approval in Q2 2019. This type of announcement, reporting significant corporate/clinical development news via an official regulatory feed, fits best under the general 'Regulatory Filings' category (RNS), as it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG). It is a general regulatory announcement.
2019-03-25 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled as an 'RNS Number' notification from the London Stock Exchange's news service. The content details 'Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them' (PDMR transactions) under MAR Regulation (Article 19). This type of mandatory disclosure regarding insider trading/director dealings is a specific regulatory filing. While it relates to director transactions (which could suggest DIRS), the format and source (RNS) strongly indicate a general regulatory announcement. Since 'Director's Dealing' (DIRS) is a specific category for reporting personal share transactions by directors, and this document perfectly matches that description (reporting acquisitions/disposals by Non-Executive Directors), DIRS is the most precise classification over the general RNS fallback. The document length is short (3898 chars), but it contains the full required disclosure, not just an announcement of a report.
2018-12-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.